GlassScriptPhysician profile
Carla D Hall
NPI 1750663803
$1,358.78
in general payments reported to CMS, 2019-2025
15 companies · $69.98 in 2025
The $69.98 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.94 · 2022: $384 · 2023: $307 · 2024: $580 · 2025: $69.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $957.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $957.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $194.67 | 2023-2025 | Farxiga, Andexxa |
| Merck Sharp & Dohme LLC | $165.91 | 2022-2024 | Verquvo |
| Boston Scientific Corporation | $145.66 | 2022-2023 | Watchman Access System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $134.86 | 2021-2024 | Lifevest |
| Amgen INC. | $131.85 | 2022-2025 | Repatha, Repatha |
| Novo Nordisk INC | $131.09 | 2023-2024 | Wegovy, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.09 | 2022-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $102.61 | 2022-2024 | Camzyos |
| Scpharmaceuticals INC. | $53.16 | 2024 | |
| Pfizer INC. | $47.28 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $42.13 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $38.43 | 2024 | Arcalyst |
| Daiichi Sankyo INC. | $31.34 | 2023 | Injectafer |
| Globus Medical, INC. | $17.67 | 2022 | |
| Impulse Dynamics (USA) INC. | $12.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carla Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.